Thermo Fisher Scientific Inc. Announces Quarterly Dividend of $0.39 (NYSE:TMO)

Thermo Fisher Scientific Inc. (NYSE:TMO) announced a quarterly dividend on Thursday, July 11th, RTT News reports. Investors of record on Friday, September 13th will be paid a dividend of 0.39 per share by the medical research company on Tuesday, October 15th. This represents a $1.56 dividend on an annualized basis and a yield of 0.25%. The ex-dividend date is Friday, September 13th.

Thermo Fisher Scientific has raised its dividend by an average of 16.7% annually over the last three years. Thermo Fisher Scientific has a dividend payout ratio of 6.5% meaning its dividend is sufficiently covered by earnings. Equities research analysts expect Thermo Fisher Scientific to earn $24.07 per share next year, which means the company should continue to be able to cover its $1.56 annual dividend with an expected future payout ratio of 6.5%.

Thermo Fisher Scientific Stock Down 0.9 %

Shares of Thermo Fisher Scientific stock opened at $618.46 on Thursday. The company has a fifty day moving average price of $589.11 and a 200 day moving average price of $579.49. The company has a current ratio of 1.72, a quick ratio of 1.37 and a debt-to-equity ratio of 0.64. Thermo Fisher Scientific has a twelve month low of $415.60 and a twelve month high of $627.88. The stock has a market cap of $236.08 billion, a price-to-earnings ratio of 39.67, a price-to-earnings-growth ratio of 2.84 and a beta of 0.78.

Thermo Fisher Scientific (NYSE:TMO) last announced its quarterly earnings results on Wednesday, July 24th. The medical research company reported $5.37 earnings per share for the quarter, topping analysts’ consensus estimates of $5.13 by $0.24. Thermo Fisher Scientific had a net margin of 14.69% and a return on equity of 18.22%. The firm had revenue of $10.54 billion during the quarter, compared to analysts’ expectations of $10.50 billion. During the same period in the prior year, the company earned $5.15 EPS. The firm’s revenue was down 1.4% on a year-over-year basis. Equities research analysts forecast that Thermo Fisher Scientific will post 21.72 earnings per share for the current fiscal year.

Insider Activity at Thermo Fisher Scientific

In related news, EVP Gianluca Pettiti sold 300 shares of the business’s stock in a transaction dated Friday, July 26th. The shares were sold at an average price of $600.85, for a total transaction of $180,255.00. Following the completion of the sale, the executive vice president now owns 17,887 shares of the company’s stock, valued at approximately $10,747,403.95. The sale was disclosed in a legal filing with the SEC, which is available through this link. In other Thermo Fisher Scientific news, CEO Marc N. Casper sold 10,000 shares of the company’s stock in a transaction dated Wednesday, July 31st. The shares were sold at an average price of $617.21, for a total value of $6,172,100.00. Following the completion of the transaction, the chief executive officer now owns 123,816 shares in the company, valued at approximately $76,420,473.36. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, EVP Gianluca Pettiti sold 300 shares of the stock in a transaction that occurred on Friday, July 26th. The shares were sold at an average price of $600.85, for a total transaction of $180,255.00. Following the completion of the transaction, the executive vice president now owns 17,887 shares of the company’s stock, valued at $10,747,403.95. The disclosure for this sale can be found here. Insiders sold a total of 23,084 shares of company stock valued at $14,094,292 in the last quarter. Insiders own 0.34% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities analysts have commented on the stock. Wells Fargo & Company assumed coverage on shares of Thermo Fisher Scientific in a report on Tuesday, August 27th. They issued an “overweight” rating and a $670.00 price objective on the stock. Evercore ISI cut their price objective on shares of Thermo Fisher Scientific from $615.00 to $600.00 and set an “outperform” rating on the stock in a report on Tuesday, July 2nd. Royal Bank of Canada boosted their price objective on shares of Thermo Fisher Scientific from $660.00 to $664.00 and gave the stock an “outperform” rating in a report on Thursday, July 25th. Robert W. Baird boosted their price objective on shares of Thermo Fisher Scientific from $620.00 to $632.00 and gave the stock an “outperform” rating in a report on Thursday, July 25th. Finally, Barclays cut their price objective on shares of Thermo Fisher Scientific from $615.00 to $600.00 and set an “equal weight” rating on the stock in a report on Friday, June 28th. Four research analysts have rated the stock with a hold rating and fifteen have issued a buy rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $630.41.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.